DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS

NEWS RELEASE

Released: January 26, 2017

Defense Health Program
Department of Defense Tuberous Sclerosis Complex Research Program
Funding Opportunities for Fiscal Year 2017 (FY17)

Due to the current Continuing Resolution, the Fiscal Year 2017 (FY17) Defense Appropriations bill has not been passed. Although funds have not been appropriated for the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP), the TSCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY17 funding opportunities.

FY17 TSCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in April 2017. Pre-application and application deadlines will be available when the Program Announcements are released. This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of Federal funds appropriated for the TSCRP.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

Focus Areas: The goal of the FY17 TSCRP is to fund pioneering and transformative science that promotes new discoveries in TSC, from mechanistic insights to clinical application. Within this context, the FY17 TSCRP encourages applications that address the critical needs of the TSC community in one or more of the following FY17 Focus Areas:

  • Understanding phenotypic heterogeneity in TSC
  • Gaining a deeper knowledge of TSC signaling pathways and the cellular consequences of TSC deficiency
  • Improving TSC disease models
  • Developing clinical biomarkers for TSC
  • Facilitating therapeutics and clinical trials research 

Award Mechanism Eligibility Key Mechanism Elements Funding
Exploration - Hypothesis Development Award Investigators at all academic levels (or equivalent), including postdoctoral fellows.
  • Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field.
  • Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
  • Preliminary data are not required.
  • Research projects must be innovative, feasible, and supported by a strong rationale.
  • Clinical trials not allowed.
  • Maximum funding of $150,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 2 years.
Idea Development Award Established Investigators:
Independent investigators at or above the level of Assistant Professor (or equivalent);

or

New Investigators:
Investigators who are early in their faculty appointments or in the process of developing independent research careers.
  • Supports new ideas that have the potential to yield high-impact findings and new avenues of investigation.
  • Preliminary data are expected.
  • Clinical trials are not allowed.
  • New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers.
    • Applications from New Investigators and Established Investigators will be peer- and programmatically reviewed separately.
  • Maximum funding of $450,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 3 years.
Clinical Translational Research Award
New!
Independent investigators at or above the level of Assistant Professor (or equivalent)
  • Supports forward or reverse clinical/translational research studies.
  • Preclinical studies that support and integrate with clinical studies are also encouraged.
  • Preliminary data are required
  • Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.
  • Maximum funding of $600,000 for direct costs (plus indirect costs).
  • Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


Last updated Wednesday, January 25, 2017